Brief: Ascletis Pharma Says Unit Got U.S. FDA Clearance For ASC42 To Initiate A Drug-Drug Interaction Study
08/06/2022 13:52
June 8 (Reuters) - Ascletis Pharma Inc 1672.HK :
* UNIT OBTAINED U.S. FDA CLEARANCE FOR ASC42 TO INITIATE A
DRUG-DRUG INTERACTION STUDY
* GANNEX EXPECTS TO COMPLETE THE DDI STUDY AT START OF Q4,
2022
Source text for Eikon: ID:nHKS5XnGkR
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026